Back to research

Research paper

Intravenous pulse methylprednisolone and corticosteroid-induced psychiatric disorders: A retrospective study

Single-center retrospective study (Japanese university hospital) of 14,585 corticosteroid recipients; 85 diagnosed with corticosteroid-induced psychiatric disorder (CIPD) (overall incidence 0.6%). Among 523 IVMP recipients, CIPD incidence was 6.1% (32/523) — about 10× higher than non-pulse use. Within IVMP-related CIPDs, post-pulse onset (22.4%) was more common than during-pulse onset (14.1%). Earlier dose-response data show 18.6% CIPDs at prednisone ≥80 mg/day vs. 1.3% at ≤40 mg/day; 75% of CIPDs are mood symptoms. Adult/mixed cohort, not pediatric.

Indexed context

Nishimura K, et al.

methylprednisoloneintravenous-pulsepsychiatric-adverse-effectscipdincidencepost-pulse-rebound

Markdown path

content/research/papers/2023-nishimura-ivmp-cipd-retrospective.md

Findings

Single-center retrospective study (Japanese university hospital) of 14,585 corticosteroid recipients; 85 diagnosed with corticosteroid-induced psychiatric disorder (CIPD) (overall incidence 0.6%). Among 523 IVMP recipients, CIPD incidence was 6.1% (32/523) — about 10× higher than non-pulse use. Within IVMP-related CIPDs, post-pulse onset (22.4%) was more common than during-pulse onset (14.1%). Earlier dose-response data show 18.6% CIPDs at prednisone ≥80 mg/day vs. 1.3% at ≤40 mg/day; 75% of CIPDs are mood symptoms. Adult/mixed cohort, not pediatric.

Why it may matter for Levi

Best available IVMP-specific incidence anchor: approximately 6% of IVMP recipients develop a clinically diagnosed psychiatric disorder, with the post-pulse window the more common emergence interval than the pulse itself. Subclinical irritability and frustration are presumably much more common than this 6% headline. Supports treating Levi's behavioral worsening 3.5 weeks after a 3-day IV methylprednisolone pulse as well within the documented natural history of IVMP rather than as evidence of relapse by itself. Pediatric data are unavailable but this is the closest IVMP-specific study.

Paper text

Nishimura et al. (2023) — IV pulse methylprednisolone and corticosteroid-induced psychiatric disorders

Source

Why this paper is in the corpus

This is one of the few studies to estimate how often intravenous pulse methylprednisolone (IVMP) — the exact class of regimen Levi received — produces a corticosteroid-induced psychiatric disorder (CIPD), and to characterize when those disorders appear relative to the pulse.

Key findings

  • Total cohort: 14,585 patients receiving any corticosteroid; 85 diagnosed with a CIPD (overall incidence 0.6%).
  • Among patients receiving IVMP (n=523), CIPD incidence was 6.1% (32/523) — about 10× higher than non-pulse use.
  • Among the IVMP-associated CIPDs, the timing distribution within the broader CIPD pool was:
    • 12 (14.1%) developed CIPDs during IVMP.
    • 19 (22.4%) developed CIPDs after IVMP.
    • 49 (57.6%) developed CIPDs without IVMP (other corticosteroid contexts).
  • The "after IVMP" category is larger than the "during IVMP" category — i.e., among IVMP-related CIPDs, more cases declared themselves after the pulse than during it.
  • Earlier dose-response data referenced in the paper show CIPDs in 18.6% of patients on prednisone ≥80 mg/day, 4.6% on 41–80 mg/day, and 1.3% on ≤40 mg/day. Of CIPD cases reviewed, 75% had mood symptoms; 77% of those used prednisolone >40 mg/day.

Limitations relevant to Levi

  • Adult/mixed hospital population; not a pediatric cohort.
  • Captures a clinical CIPD diagnosis (which selects for severity); subclinical or "subsyndromal" mood/irritability changes are presumably much more common and would not be counted.
  • Does not report exact timing distributions in days or weeks for the "after IVMP" subgroup.

Levi-relevant takeaways

  • Establishes a credible base rate: ~6% of IVMP recipients develop a clinically diagnosed psychiatric disorder, and the post-pulse interval is the more common emergence window than the pulse itself. Subclinical irritability and frustration are presumably much more common than this 6% headline.
  • Supports treating "behavioral worsening 3.5 weeks after a 3-day IV methylprednisolone pulse" as well within the documented natural history of IVMP, not as evidence of relapse by itself.
  • Pediatric incidence cannot be extrapolated directly, but this study is the closest IVMP-specific anchor available.